- Home
- HSPO vs ADAG Comparison
HSPO vs ADAG Comparison
Compare HSPO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- ADAG
- Stock Information
- Founded
- HSPO 2014
- ADAG 2011
- Country
- HSPO United States
- ADAG China
- Employees
- HSPO N/A
- ADAG N/A
- Industry
- HSPO Blank Checks
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- ADAG Health Care
- Exchange
- HSPO Nasdaq
- ADAG Nasdaq
- Market Cap
- HSPO 92.0M
- ADAG 81.9M
- IPO Year
- HSPO 2022
- ADAG 2021
- Fundamental
- Price
- HSPO $11.80
- ADAG $1.52
- Analyst Decision
- HSPO
- ADAG Strong Buy
- Analyst Count
- HSPO 0
- ADAG 1
- Target Price
- HSPO N/A
- ADAG $8.00
- AVG Volume (30 Days)
- HSPO 1.4K
- ADAG 40.1K
- Earning Date
- HSPO 01-01-0001
- ADAG 03-24-2025
- Dividend Yield
- HSPO N/A
- ADAG N/A
- EPS Growth
- HSPO 2.63
- ADAG N/A
- EPS
- HSPO 0.91
- ADAG N/A
- Revenue
- HSPO N/A
- ADAG $103,204.00
- Revenue This Year
- HSPO N/A
- ADAG N/A
- Revenue Next Year
- HSPO N/A
- ADAG $2.70
- P/E Ratio
- HSPO $12.82
- ADAG N/A
- Revenue Growth
- HSPO N/A
- ADAG N/A
- 52 Week Low
- HSPO $10.87
- ADAG $1.39
- 52 Week High
- HSPO $12.41
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- HSPO 52.89
- ADAG 32.38
- Support Level
- HSPO $11.61
- ADAG $1.39
- Resistance Level
- HSPO $11.75
- ADAG $1.83
- Average True Range (ATR)
- HSPO 0.00
- ADAG 0.16
- MACD
- HSPO 0.00
- ADAG -0.03
- Stochastic Oscillator
- HSPO 50.00
- ADAG 24.23
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.